Sponsored byOpenSourceMed

Spike Protein Clearance: Treatments & Evidence Levels

Interventions proposed to neutralise, degrade or remove SARS-CoV-2 spike protein, grouped by the strongest evidence behind each one. No treatment is established for clearing spike protein.

Treatments by evidence level

Tested in randomised trials

Randomised trials or regulatory review exist, but for acute COVID-19 or prophylaxis. None has been shown in a trial to clear persistent or vaccine-derived spike.

  • Pemivibart (INV-202)

    Monoclonal antibody · FDA-authorized

    Neutralizes spike; prevents ACE2 binding

    Status: Authorized for immunocompromised pre-exposure prophylaxis

    Limitations: Not approved for long COVID or vaccine-spike clearance

  • Sotrovimab

    Monoclonal antibody · FDA-authorized

    Spike neutralization (conserved epitope)

    Status: Authorization withdrawn in many regions (variant escape)

    Limitations: Acute COVID-19 only; limited variant coverage

  • Evusheld (tixagevimab/cilgavimab)

    Monoclonal antibody combo · FDA-authorized

    Dual spike neutralization

    Status: EU authorization reduced/withdrawn due to variant escape

    Limitations: Prophylaxis only; not for established spike persistence

  • Ivermectin

    Antiparasitic · RCT negative/mixed

    Docks to spike RBD-ACE2 interface (in silico/docking)

    Status: Not recommended for COVID-19 (major RCTs negative)

    Limitations: Docking study only; clinical RCTs failed primary endpoints

  • Quercetin

    Flavonoid · RCT negative/mixed

    TMPRSS2 inhibition; proposed ACE2/spike interface disruption (docking)

    Status: OTC supplement; some meta-analyses for acute COVID

    Limitations: Bioavailability poor; long COVID RCT data lacking

  • Colchicine

    Anti-inflammatory · RCT negative/mixed

    Anti-inflammatory; indirect reduction of spike-mediated inflammation

    Status: Acute COVID trials mixed; not spike-directed

    Limitations: Does not directly block or degrade spike

  • Azithromycin

    Antibiotic · RCT negative/mixed

    Proposed CD147 pathway interference (contested target)

    Status: Acute COVID trials generally negative

    Limitations: Not spike-specific; CD147 as a spike coreceptor is itself scientifically contested

  • Nirmatrelvir/ritonavir (Paxlovid)

    Antiviral · FDA-approved (COVID-19)

    Inhibits viral replication; may reduce spike production during active infection

    Status: Approved acute COVID-19; long COVID prevention trials mixed

    Limitations: Not designed for vaccine-derived spike clearance

  • Remdesivir

    Antiviral · FDA-approved (COVID-19)

    Reduces viral replication → less neoantigen production

    Status: Hospitalized COVID-19

    Limitations: No role in established spike persistence without active infection

Trials under way

Registered trials in Long COVID or post-vaccination illness; results pending.

  • SPEAR Trial (spike-directed apheresis)

    Clinical trial · Ongoing trial

    Protocolized spike reduction via apheresis

    Status: Recruiting

    Limitations: Results pending

  • Metformin

    Autophagy inducer (off-label proposals) · Ongoing trial

    Upregulates autophagy; proposed spike aggregate clearance

    Status: NCT03996538 (vaccine response); long COVID interest

    Limitations: Autophagy hypothesis; no completed long COVID spike-clearance RCT

  • NIH RECOVER

    Research program · Ongoing trial

    Multi-intervention long COVID trials

    Status: Ongoing

    Limitations: Not exclusively spike-targeted

Case series or pilot studies

Small, usually uncontrolled human studies. They can suggest a signal but cannot show that the treatment caused any improvement.

  • Therapeutic apheresis / plasmapheresis

    Blood purification · Case series / pilot

    Physical removal of circulating spike, autoantibodies, lipids

    Status: SPEAR trial ongoing; Achleitner et al. long-COVID pilot

    Limitations: No large RCT; invasive; symptom improvement in subsets only

  • N-Acetylcysteine (NAC)

    Antioxidant / mucolytic · Case series / pilot

    Thiol/disulfide exchange weakens spike-ACE2 binding affinity; glutathione precursor

    Status: Used off-label; COVID-19 pilot studies

    Limitations: In vitro binding-affinity data; heterogeneous clinical endpoints

  • Anti-CD147 antibody (meplazumab)

    Monoclonal antibody · Case series / pilot

    Blocks CD147–spike interaction

    Status: Investigated in China for acute COVID

    Limitations: CD147 as a direct spike-binding receptor is disputed by independent replication studies; limited Western regulatory approval

  • NRICM101 (traditional formula)

    Herbal compound · Case series / pilot

    Neurovascular protection in spike-administered hACE2 mice

    Status: Investigated for brain fog in animal models

    Limitations: Animal data; limited Western RCTs

  • Hyperbaric oxygen (HBOT)

    Adjunct therapy · Case series / pilot

    Tissue oxygenation; proposed neurovascular recovery

    Status: Pilot long COVID studies

    Limitations: Does not directly degrade spike; expensive

  • Low-dose naltrexone (LDN)

    Immunomodulator · Case series / pilot

    Immune modulation in long COVID (not spike-specific)

    Status: Off-label use reported

    Limitations: No spike degradation/blockade demonstrated

Lab-only (cell, enzyme or computer studies)

Activity against spike shown in a test tube, cell culture or docking model. No human data showing spike clearance.

  • Nattokinase

    Protease supplement · In vitro / in silico only

    In vitro degradation of recombinant spike at 2.5–25 µg/mL

    Status: Dietary supplement; not FDA-approved as drug

    Limitations: No human RCT for spike clearance; bleeding risk in pregnancy

  • Bromelain

    Protease supplement · In vitro / in silico only

    Spike degradation and competitive inhibition of spike–ACE2 binding

    Status: OTC supplement

    Limitations: Limited spike-specific human data; bleeding caution in pregnancy

  • Curcumin

    Polyphenol · In vitro / in silico only

    Virtual screening indicates spike/ACE2 binding inhibition

    Status: Supplement

    Limitations: Poor bioavailability; no spike-clearance RCT

  • Spermidine / resveratrol

    Autophagy-promoting nutraceuticals · In vitro / in silico only

    Autophagy upregulation

    Status: Supplements

    Limitations: No clinical spike-clearance validation

Theoretical

Proposed in reviews or from mechanism alone, without direct experimental data on spike.

  • Lumbrokinase / serrapeptase

    Fibrinolytic enzymes · Theoretical / review only

    Fibrin degradation; proposed microclot clearance

    Status: Supplements; used off-label in some protocols

    Limitations: No RCT for long COVID; indirect mechanism vs. direct spike degradation

  • Nicotine / α7nAChR agonism

    Cholinergic modulator · Theoretical / review only

    α7nAChR agonism to counteract spike-mediated receptor downregulation; anti-inflammatory

    Status: Hypothesis; not standard of care

    Limitations: Addiction liability; limited long COVID clinical trials

  • Rapamycin (sirolimus)

    mTOR inhibitor / autophagy inducer · Theoretical / review only

    Autophagy enhancement; proposed clearance of spike aggregates

    Status: Investigational; immunosuppression limits use

    Limitations: No human long COVID RCT; immunosuppressive

  • Intermittent fasting / caloric restriction

    Lifestyle intervention · Theoretical / review only

    Fasting-induced autophagy; proposed spike clearance

    Status: Proposed in autophagy literature

    Limitations: No controlled long COVID fasting RCT

Compare all interventions

Interventions claimed to block spike–receptor binding, degrade spike protein, or clear circulating spike/autoantibodies. Clinical support tiers reflect published RCTs, authorization status, or preclinical data only.

Spike-blocking and spike-degrading therapeutics for COVID-19 and long COVID
Claimed mechanismLimitationsSource
Pemivibart (INV-202)Track on OSMF Research Tracker →Monoclonal antibodyReceptor/entry blockadeblockFDA-authorizedNoNeutralizes spike; prevents ACE2 bindingNot approved for long COVID or vaccine-spike clearance
SotrovimabTrack on OSMF Research Tracker →Monoclonal antibodyReceptor/entry blockadeblockFDA-authorizedNoSpike neutralization (conserved epitope)Acute COVID-19 only; limited variant coverage
Evusheld (tixagevimab/cilgavimab)Track on OSMF Research Tracker →Monoclonal antibody comboReceptor/entry blockadeblockFDA-authorizedNoDual spike neutralizationProphylaxis only; not for established spike persistence
Therapeutic apheresis / plasmapheresisTrack on OSMF Research Tracker →Blood purificationEnzymatic or physical clearanceclearCase series / pilotYesPhysical removal of circulating spike, autoantibodies, lipidsNo large RCT; invasive; symptom improvement in subsets onlyAchleitner M, et al. (2023)Opens in new tabClinicalTrials.gov (2024)Opens in new tab
SPEAR Trial (spike-directed apheresis)Track on OSMF Research Tracker →Clinical trialEnzymatic or physical clearanceclearOngoing trialYesProtocolized spike reduction via apheresisResults pendingClinicalTrials.gov (2024)Opens in new tab
NattokinaseTrack on OSMF Research Tracker →Protease supplementEnzymatic or physical clearancedegradeIn vitro / in silico onlyYesIn vitro degradation of recombinant spike at 2.5–25 µg/mLNo human RCT for spike clearance; bleeding risk in pregnancyTanikawa T, et al. (2022)Opens in new tab
BromelainTrack on OSMF Research Tracker →Protease supplementEnzymatic or physical clearancedegradeIn vitro / in silico onlyYesSpike degradation and competitive inhibition of spike–ACE2 bindingLimited spike-specific human data; bleeding caution in pregnancySagar S, et al. (2021)Opens in new tab
Lumbrokinase / serrapeptaseTrack on OSMF Research Tracker →Fibrinolytic enzymesEnzymatic or physical clearanceindirectTheoretical / review onlyYesFibrin degradation; proposed microclot clearanceNo RCT for long COVID; indirect mechanism vs. direct spike degradationHalma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab
IvermectinTrack on OSMF Research Tracker →AntiparasiticReceptor/entry blockadeblockRCT negative/mixedNoDocks to spike RBD-ACE2 interface (in silico/docking)Docking study only; clinical RCTs failed primary endpointsVarious (2020)Opens in new tab
QuercetinTrack on OSMF Research Tracker →FlavonoidReceptor/entry blockadeblockRCT negative/mixedYesTMPRSS2 inhibition; proposed ACE2/spike interface disruption (docking)Bioavailability poor; long COVID RCT data lackingVarious (2022)Opens in new tab
Nicotine / α7nAChR agonismTrack on OSMF Research Tracker →Cholinergic modulatorAnti-inflammatory / immunomodulatorybothTheoretical / review onlyYesα7nAChR agonism to counteract spike-mediated receptor downregulation; anti-inflammatoryAddiction liability; limited long COVID clinical trialsTillman TS, Chen Q, Bondarenko V, Coleman JA, Xu Y, Tang P (2023)Opens in new tabVarious (2023)Opens in new tab
N-Acetylcysteine (NAC)Track on OSMF Research Tracker →Antioxidant / mucolyticAnti-inflammatory / immunomodulatorybothCase series / pilotYesThiol/disulfide exchange weakens spike-ACE2 binding affinity; glutathione precursorIn vitro binding-affinity data; heterogeneous clinical endpointsVarious (2022)Opens in new tab
CurcuminTrack on OSMF Research Tracker →PolyphenolAnti-inflammatory / immunomodulatoryindirectIn vitro / in silico onlyYesVirtual screening indicates spike/ACE2 binding inhibitionPoor bioavailability; no spike-clearance RCTVarious (2020)Opens in new tab
ColchicineTrack on OSMF Research Tracker →Anti-inflammatoryAnti-inflammatory / immunomodulatoryindirectRCT negative/mixedNoAnti-inflammatory; indirect reduction of spike-mediated inflammationDoes not directly block or degrade spike
MetforminTrack on OSMF Research Tracker →Autophagy inducer (off-label proposals)Autophagy inductionclearOngoing trialYesUpregulates autophagy; proposed spike aggregate clearanceAutophagy hypothesis; no completed long COVID spike-clearance RCTHalma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab
Rapamycin (sirolimus)Track on OSMF Research Tracker →mTOR inhibitor / autophagy inducerAutophagy inductionclearTheoretical / review onlyYesAutophagy enhancement; proposed clearance of spike aggregatesNo human long COVID RCT; immunosuppressiveHalma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab
Spermidine / resveratrolTrack on OSMF Research Tracker →Autophagy-promoting nutraceuticalsAutophagy inductionclearIn vitro / in silico onlyYesAutophagy upregulationNo clinical spike-clearance validationHalma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab
Intermittent fasting / caloric restrictionTrack on OSMF Research Tracker →Lifestyle interventionAutophagy inductionclearTheoretical / review onlyYesFasting-induced autophagy; proposed spike clearanceNo controlled long COVID fasting RCTHalma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab
AzithromycinTrack on OSMF Research Tracker →AntibioticReceptor/entry blockadeblockRCT negative/mixedNoProposed CD147 pathway interference (contested target)Not spike-specific; CD147 as a spike coreceptor is itself scientifically contested
Anti-CD147 antibody (meplazumab)Track on OSMF Research Tracker →Monoclonal antibodyReceptor/entry blockadeblockCase series / pilotNoBlocks CD147–spike interactionCD147 as a direct spike-binding receptor is disputed by independent replication studies; limited Western regulatory approvalWang K, et al. (2020)Opens in new tab
Nirmatrelvir/ritonavir (Paxlovid)Track on OSMF Research Tracker →AntiviralAntiviral (indirect)indirectFDA-approved (COVID-19)YesInhibits viral replication; may reduce spike production during active infectionNot designed for vaccine-derived spike clearance
RemdesivirTrack on OSMF Research Tracker →AntiviralAntiviral (indirect)indirectFDA-approved (COVID-19)NoReduces viral replication → less neoantigen productionNo role in established spike persistence without active infection
NIH RECOVERTrack on OSMF Research Tracker →Research programMulti-modal research programindirectOngoing trialYesMulti-intervention long COVID trialsNot exclusively spike-targetedNIH RECOVER Initiative (2024)Opens in new tab
NRICM101 (traditional formula)Track on OSMF Research Tracker →Herbal compoundMulti-modal research programindirectCase series / pilotYesNeurovascular protection in spike-administered hACE2 miceAnimal data; limited Western RCTsChang CC, et al. (2024)Opens in new tab
Hyperbaric oxygen (HBOT)Track on OSMF Research Tracker →Adjunct therapyAnti-inflammatory / immunomodulatoryindirectCase series / pilotYesTissue oxygenation; proposed neurovascular recoveryDoes not directly degrade spike; expensive
Low-dose naltrexone (LDN)Track on OSMF Research Tracker →ImmunomodulatorAnti-inflammatory / immunomodulatoryindirectCase series / pilotYesImmune modulation in long COVID (not spike-specific)No spike degradation/blockade demonstrated

Clinical support legend

  • FDA-approved/authorized — Regulatory approval for acute COVID-19 or prophylaxis; not necessarily long COVID or vaccine-spike clearance.
  • RCT positive/negative — Randomized trial outcomes for claimed indication.
  • Case series / pilot — Small human studies (e.g., Achleitner apheresis long-COVID cohort).
  • In vitro only — No robust human efficacy (e.g., nattokinase 2.5–25 µg/mL cell-free degradation).
  • Theoretical — Review or pharmacogenomic rationale without clinical validation.

Clinical caution

No intervention is established standard of care for vaccine-derived spike clearance. Nattokinase and bromelain carry bleeding-risk cautions in pregnancy/breastfeeding.